Don’t prescribe generic Lyrica for nerve pain, Pfizer warns UK

15 Jan 2015

Pfizer has written doctors in the UK warning them not to prescribe generic Lyrica (pregabalin)  to treat neuropathic pain. The company still has a live patent covering Lyrica’s use against nerve pain and the generics are specifically approved to treat generalized anxiety disorder and epilepsy. According to the letter published on patentdocs website Pfizer states it’s seeking to “inform” recipients about “relatively unusual issues” affecting Lyrica exclusivity, “so that you can take necessary action to prevent patent infringement by your organization.”

“Pfizer believes the supply of generic pregabalin for use in the treatment of pain whilst the pain patent remains in force in the U.K. would infringe Pfizer’s patent rights,” the letter states.




Already a member?

Login to keep reading.

Email me a login link